However, as there is ample evidence supporting the use of β-blockers, ACE-I and/or ARB in patients with heart failure, which include current guidelines [18-20], results of this analysis could give a good estimate of spironolactone use in a real-life context despite study limitations. Here, ACE is linked to heart failure.